Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Finerenone on Renal Hemodynamics and Oxidative Stress
NCT06244758Phase 3Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Jan 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Finerenone 20 MG Oral Tablet with Placebo (2 arms). Primary endpoint: Impact of finerenone on the oxidative stress level of renal vasculature at 3 months. Started Jan 2024; status: completed.
02
Drugs
finerenone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06244758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06244758.